1,720,975 research outputs found
Glucuronxylomannan, a major capsular component of Cryptococcus neoformans, accumulates in human monocytes and neutrophils
Regulatory role exogenus interleukin 10 in the development of immune response versus Cryptococcus neoformans
Role of accessory molecules in the regulation of protective immunity against Cryptococcus neoformans
The expression and biological activity of CD88 (C5aR)on human neutrophils are limited by capsular material of Cryptococcus neoformans
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes
The regulation by Cryptococcus neoformans encapsulation of interleukin 1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) production by human monocytes was investigated. By using encapsulated and acapsular C. neoformans, we demonstrated that both strains induce cytokine production, although the acapsular strain was a better stimulator than the thinly encapsulated strain. The cytokine levels produced by cells stimulated by the two strains were lower and followed a different kinetic than those stimulated by lipopolysaccharide (LPS). Purified capsular polysaccharide inhibits TNF-alpha secretion induced by LPS or acapsular C. neoformans. In contrast, no regulator effect on IL-1 beta was observed when LPS was used. The secretory response of these cytokines follows different pathways of macrophage activation; in fact, complete inhibition of TNF-alpha does not affect IL-1 beta production and vice versa. These data indicate that purified capsular polysaccharide of C. neoformans could contribute to the in vivo progress of cryptococcosis by suppressing cytokine production of macrophages and suggest that a therapeutic approach to address the suppressive effect of cryptococal polysaccharide could be devised
BENEFICIAL EFFECT OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR ON FUNGICIDAL ACTIVITY OF POLYMORPHONUCLEAR LEUKOCYTES FROM PATIENTS WITH AIDS
The effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on the functional status of polymorphonuclear leukocytes (PMNL) in neutropenic AIDS patients was investigated. PMNL destructive activity against Candida albicans or encapsulated or acapsular Cryptococcus neoformans was significantly impaired with respect to control subjects before rhG-CSF treatment. After subcutaneous administration of rhG-CSF (5 mu g/kg), neutrophil counts increased 3- to 11-fold in 24 h and returned to baseline within 96 h. PMNL fungicidal activity showed significant enhancement 48-72 h after rhG-CSF administration that decreased to baseline within 96 h. Enhanced rhG-CSF-mediated destructive activity strictly correlated with augmented superoxide anion production by PMNL. These findings suggest that therapeutic use of rhG-CSF at appropriate schedules in neutropenic AIDS patients could decrease the risk of infection or, in association with antibiotic therapy, more rapidly resolve the occurring infections
La glicoproteina virale gp120 del virus HIV-1 influenza l'espressione di molecole costimolatorie sulle cellule presentanti l'antigene e altera le risposte T cellulari verso Cryptococcus neoformans
Differente espressione del C5aR e del FcgammaRIII sulla superficie di neutrofili provenienti da pazienti con AIDS
- …
